(-0.01%) 5 478.00 points
(-0.04%) 38 803 points
(0.04%) 19 929 points
(0.27%) $80.55
(1.15%) $2.82
(0.15%) $2 332.40
(-0.26%) $29.32
(-0.10%) $969.90
(0.02%) $0.932
(-0.15%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States...
Stats | |
---|---|
Šios dienos apimtis | 5.38M |
Vidutinė apimtis | 787 717 |
Rinkos kapitalizacija | 12.11M |
EPS | $-0.0111 ( Q2 | 2023-08-14 ) |
Kita pelno data | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.867 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0180 (11.61%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Fr Capital Holdings, L.p. | Sell | 50 000 | Ordinary Shares, par value NIS 0.35 each |
2023-12-28 | Fr Capital Holdings, L.p. | Sell | 21 500 | Ordinary Shares, par value NIS 0.35 each |
2023-12-29 | Fr Capital Holdings, L.p. | Sell | 6 000 | Ordinary Shares, par value NIS 0.35 each |
2023-12-26 | Fr Capital Holdings, L.p. | Sell | 11 456 | Ordinary Shares, par value NIS 0.35 each |
2023-12-27 | Fr Capital Holdings, L.p. | Sell | 20 033 | Ordinary Shares, par value NIS 0.35 each |
INSIDER POWER |
---|
-43.47 |
Last 32 transactions |
Buy: 525 000 | Sell: 1 196 932 |
Tūris Koreliacija
Vascular Biogenics Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Vascular Biogenics Ltd Koreliacija - Valiuta/Žaliavos
Vascular Biogenics Ltd Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $658 000 |
Bruto pelnas: | $554 000 (84.19 %) |
EPS: | $-0.420 |
FY | 2022 |
Pajamos: | $658 000 |
Bruto pelnas: | $554 000 (84.19 %) |
EPS: | $-0.420 |
FY | 2021 |
Pajamos: | $768 000 |
Bruto pelnas: | $403 000 (52.47 %) |
EPS: | $-0.685 |
FY | 2020 |
Pajamos: | $922 000 |
Bruto pelnas: | $528 000 (57.27 %) |
EPS: | $-0.550 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Vascular Biogenics Ltd
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.